Richard Lund, MD
Nephrology · Omaha, NENPI 1609969468
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $312,022 of the $377,524 with a category attached, or 82.6%. 31 manufacturers reported payments, led by Bayer at 39.6% of the total. 2025 is the largest year on record at $92,240, 2.1 times the $44,235 reported in 2019. Among nephrology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 637 payments — averaging $592.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$149K
- ANI Pharmaceuticals, Inc.$58K
- Calliditas Therapeutics US Inc.$49K
- Vifor Pharma, Inc.$46K
- Travere Therapeutics, Inc.$46K
- Akebia Therapeutics Inc$20K
- plus $10K from 25 others
What the payments were for
- Consulting fees$11,1453%
- Speaking & faculty fees$312,02283%
- Travel & lodging$41,10511%
- Food & beverage$13,1493%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 183 | $149,349 |
| ANI Pharmaceuticals, Inc. | 116 | $58,078 |
| Calliditas Therapeutics US Inc. | 59 | $48,522 |
| Vifor Pharma, Inc. | 73 | $45,576 |
| Travere Therapeutics, Inc. | 113 | $45,515 |
| Akebia Therapeutics Inc | 20 | $19,992 |
| Mallinckrodt Enterprises LLC | 13 | $7,873 |
| AstraZeneca | 11 | $444 |
| Bard Peripheral Vascular, Inc. | 4 | $411 |
| Amgen | 8 | $244 |
| Medtronic | 1 | $177 |
| Scpharmaceuticals Inc. | 3 | $168 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $164 |
| Sanofi | 2 | $149 |
| Nxstage Medical, Inc. | 2 | $135 |
| Ardelyx, Inc. | 1 | $133 |
| Mallinckrodt Hospital Products Inc. | 5 | $126 |
| Johnson & Johnson | 1 | $100 |
| Otsuka America Pharmaceutical, Inc. | 4 | $74 |
| Boehringer Ingelheim | 3 | $58 |
| GSK | 3 | $45 |
| Cormedix Inc. | 1 | $29 |
| Lilly USA, LLC | 1 | $24 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| Novo Nordisk | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Outset Medical Inc | 1 | $17 |
| Mozarc Medical US LLC | 1 | $17 |
| Fresenius USA Marketing, Inc. | 1 | $17 |
| Novartis | 1 | $14 |
| Aurinia Pharma U.S., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$146,820
- PURIFIED CORTROPHIN GEL$56,298
- TARPEYO$47,843
- Veltassa$27,805
- AURYXIA$19,624
- Filspari$17,317
- ACTHAR$7,669
- SYMPLICITY G3$177
- Pristine$153
- IBSRELA$133
- FUROSCIX$120
- FABRAZYME$119
- PUREFLOW SL$115
- NXSTAGE SYSTEM ONE$115
- Tavneos$104
How this compares
$377,524 in reported general payments places this provider in the 95th percentile of 60 nephrology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 200 | $158,732 |
| FarxigaDapagliflozin Propanediol | 76 | $49,806 |
| JardianceEmpagliflozin | 56 | $42,789 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $10,529 |
| Sevelamer Carbonate | 64 | $9,134 |
| Calcitriol | 183 | $3,025 |
| Mycophenolic AcidMycophenolate Sodium | 11 | $2,665 |
| Bumetanide | 64 | $1,645 |
| Torsemide | 93 | $1,462 |
| Potassium Citrate ErPotassium Citrate | 15 | $1,173 |
| Febuxostat | 18 | $1,060 |
| Losartan Potassium | 188 | $1,003 |
| Calcium Acetate | 21 | $902 |
| Amlodipine Besylate | 195 | $808 |
| Furosemide | 174 | $650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerKerendia | $149,349 | $158,732200 claims |
| AstraZenecaFarxiga | $444 | $49,80676 claims |
| Boehringer IngelheimJardiance | $58 | $42,78956 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $58,078 | $9615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 60 nephrology providers in Nebraska.
Other nephrology in Omaha
- Jeffrey PasserOmaha$146K
- Roslyn MannonOmaha$64K
- Troy PlumbOmaha$17K
- Eric MagliuloOmaha$9K
- Prasanth RavipatiOmaha$7K
- Joseph BastOmaha$5K
- Stefan HemmingsOmaha$5K
- Sunil JagadeshOmaha$4K
- Judd BauerOmaha$3K
- Mohammed NazmulOmaha$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.